Barely an hour after being wheeled into a clinical space at Oregon Health & Science University on Aug. 27, an Arkansas woman emerged with vastly improved symptoms of the Parkinson's disease that had ...

The NIH has awarded a $3 million research grant to CND Life Sciences to initiate a 3-year multicenter study to evaluate the validity of a skin punch biopsy test to determine risk for Parkinson’s ...

Investors looking for stocks that can produce eye-popping gains in a short time frame often turn toward biotechnology stocks. In this wonky industry, encouraging results from a clinical trial can turn ...

Transcutaneous afferent patterned stimulation is linked to metabolic activity changes in the cerebellum and other brain areas ...

The company plans to conduct a three-year study of Parkinson's risk among people with essential tremor, using its Syn-One Test.

Abstract: Tremor is one of the most prevalent movement disorders, which is especially observed in patients with Parkinson’s disease (PD) and other conditions common in palliative care (PC). Effective ...

DelveInsight’s “Essential Tremor Pipeline Insight 2025” report provides comprehensive insights about 7+ companies and 10+ pipeline drugs in the Essential Tremor pipeline landscape. It covers the ...

Bolstered by a late-stage trial win for its essential tremor drug, Praxis Precision Medicines Inc. is looking to raise $525 million in a public offering.

TD Cowen raised Praxis Precision Medicines price target from $61 to $251, maintaining a Buy rating after strong Phase 3 results Ulixacaltamide HCl met primary endpoints in both essential tremor ...

Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of Daily Living 11 at Week 8, the pre-specified primary ...